Vor Biopharma Inc. — Q2 2023 Form 10-Q
Reporting period: Three and six months ended June 30, 2023. Vor is a clinical-stage cell and genome engineering company with no approved products and no product revenue.
Financial performance and position
| Metric | Q2 2023 | Q2 2022 | Six months 2023 | Six months 2022 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Research and development expense | $23.9m | $15.3m | $45.8m | $30.6m |
| General and administrative expense | $8.3m | $6.5m | $16.8m | $14.0m |
| Total operating expenses | $32.2m | $21.8m | $62.6m | $44.6m |
| Net loss | $30.0m | $21.7m | $58.4m | $44.4m |
| Net loss per share, basic and diluted | $0.45 | $0.58 | $0.88 | $1.19 |
| Interest income | $2.2m | $0.1m | $4.2m | $0.2m |
At June 30, 2023, cash and cash equivalents were $32.2m and marketable securities were $154.7m, totaling $186.9m; restricted cash was an additional $2.4m. Total assets were $251.0m and stockholders’ equity was $204.5m. Vor reported no debt outstanding. Operating lease liabilities totaled $37.5m. Gross margin is not applicable because the company had no revenue.
For the first six months, operating cash use was $48.4m, compared with $47.9m a year earlier. Investing activities provided $20.1m, primarily from marketable-security maturities, while financing provided $2.7m. Cash, cash equivalents and restricted cash decreased by $25.5m to $34.6m.
Material changes versus prior periods
- Q2 net loss increased $8.3m year over year; first-half net loss increased $14.0m.
- First-half R&D expense rose $15.2m, reflecting clinical, manufacturing and consulting costs for trem-cel and VCAR33, added personnel, and expanded laboratory and manufacturing facilities. G&A expense increased $2.8m.
- First-half interest income increased $4.0m, partly offsetting higher operating expenses and reflecting higher returns on cash and investments.
- Cash, cash equivalents and marketable securities declined from $230.2m at year-end 2022 to $186.9m at June 30, 2023. Vor raised $4.3m net through its ATM facility in the first half; $120.6m remained available under that facility.
Outlook, developments and risks
- Management expects June 30 cash, cash equivalents and marketable securities to fund operating expenses and capital needs into the first quarter of 2025. The financial-statement note separately says resources should cover at least one year after the statements’ issuance; these are differently framed runway statements.
- Vor expects continued operating losses and rising R&D spending, and says it will need additional capital. Future financing may dilute shareholders; funding may not be available on acceptable terms, and inability to obtain funding could force program reductions or threaten continued operations.
- Vor reported June 2023 clinical data from the Phase 1/2a VBP101 trem-cel trial and expects further engraftment and hematologic-protection data by year-end 2023. The FDA cleared the VCAR33 ALLO IND in June 2023, permitting a planned Phase 1/2 VBP301 trial.
- The company’s new in-house facility completed cGMP qualification and can begin clinical manufacturing of VCAR33 ALLO. Vor said it remained on track to begin in-house trem-cel manufacturing in 2023, while retaining third-party manufacturing as backup.
- Vor plans to obtain initial trem-cel and VCAR33 ALLO clinical data before submitting an IND for the combined Treatment System. Trial timing, enrollment, results, regulatory progress, manufacturing execution, and financing are subject to significant uncertainty.
- Vor disclosed no material changes to the risk factors in its 2022 Form 10-K, no material legal proceedings, and no material off-balance-sheet arrangements. Management said disclosure controls were effective and there were no material changes to internal control over financial reporting.
Key facts for investors to verify
- Whether clinical updates and trial milestones occur on the stated timelines, and what the data show regarding safety, engraftment and hematologic protection.
- Whether the projected cash runway into Q1 2025 remains supportable as spending increases; reconcile this outlook with the financial-statement note’s one-year sufficiency statement.
- Future cash burn, financing needs, ATM usage and potential dilution, including the effect of additional equity or other financing.
- Progress and costs of VCAR33 ALLO and trem-cel manufacturing, including in-house readiness and reliance on third parties.
- Lease commitments and other contingent or milestone-based obligations under vendor, license and collaboration agreements.